Christophe Bonnet

Liege, WAL, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Journal: Blood advances
Published: February 19, 2026

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Journal: Blood advances
Published: February 19, 2026

Performance of artificial intelligence in the collection of patient history in general practice.

Performance of artificial intelligence in the collection of patient history in general practice.

Journal: Atencion primaria
Published: February 05, 2026

Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Journal: Leukemia
Published: November 20, 2025

Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Journal: Leukemia
Published: July 28, 2025

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 20, 2025

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 20, 2025

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.

Journal: Hematological oncology
Published: April 01, 2025

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Journal: Blood advances
Published: January 02, 2025

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Journal: Blood advances
Published: December 10, 2024

Image of cerebral leukostasis in a context of acute leukemia

Image of cerebral leukostasis in a context of acute leukemia

Journal: Revue medicale de Liege
Published: November 15, 2024

Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA.

Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA.

Journal: EClinicalMedicine
Published: October 25, 2024
Showing 1-12 of 68

Last Updated: 09/26/2026